MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

1. Ferrer, I.
2. Quintanal-Villalonga, Á.
3. Molina-Pinelo, S.
4. Garcia-Heredia, J.M.
5. Perez, M.
6. Suárez, R.
7. Ponce-Aix, S.
8. Paz-Ares, L.
9. Carnero, A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1186/S13046-018-0871-7 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus